How does Linzess (linaclotide) work?

How Linzess (Linaclotide) Works

Linzess works by activating guanylate cyclase-C (GC-C) receptors on the intestinal epithelial cells, which increases cyclic GMP production, leading to chloride and bicarbonate secretion into the intestinal lumen—this increases intestinal fluid, accelerates GI transit, and reduces visceral pain signaling. 1, 2

Mechanism of Action: A Two-Pronged Approach

1. Intestinal Secretion and Transit

Linaclotide is a 14-amino acid peptide that structurally mimics human guanylin and uroguanylin 2. When you take it orally:

• It acts locally on the luminal surface of the intestinal epithelium—it is minimally absorbed with negligible systemic availability 2
• Binds to GC-C receptors expressed on intestinal epithelial cells (not on neurons) 3
• Activates intracellular cGMP production, which then:
  • Stimulates the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel 1, 2
  • Drives chloride and bicarbonate secretion into the intestinal lumen 1
  • Increases intestinal fluid content 2
  • Accelerates gastrointestinal transit 1

2. Pain Reduction Through Extracellular cGMP

The analgesic mechanism is distinct and clinically important 3:

• cGMP is released from epithelial cells into the extracellular space after GC-C activation 3
• This extracellular cGMP directly inhibits colonic nociceptors (pain-sensing nerves) 3
• Reduces visceral hypersensitivity by decreasing the activity of pain-sensing nerves and reducing signaling of noxious stimuli to the spinal cord 3
• This explains why linaclotide improves abdominal pain, bloating, and discomfort in IBS-C patients—not just constipation 1

Clinical Implications

The drug works entirely within the GI tract 2:

• Metabolism occurs within the gastrointestinal tract by loss of the terminal tyrosine, creating an active metabolite 2
• Both linaclotide and its metabolite are then degraded to smaller peptides and amino acids 2
• Plasma concentrations are below the limit of quantitation—no measurable systemic absorption 2
• This local action explains the favorable safety profile with minimal systemic adverse effects 1

Key Practical Points

Administration matters: Take on an empty stomach at least 30 minutes before the first meal of the day 1. Taking it with food (especially high-fat meals) results in looser stools and higher stool frequency 2.

Dosing by indication 1:

• Chronic idiopathic constipation: 72 mcg or 145 mcg daily
• IBS-C: 290 mcg daily

The most common adverse effect is diarrhea (16-20% in trials), which led to discontinuation in only 4.7% of patients 1. This is mechanistically predictable given the drug's secretory action.

Contraindication: Known or suspected mechanical GI obstruction 1.